Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO) and InnoCare Pharma Limited (&ldqu...
The €190 million acquisition of VISUfarma marks a pivotal moment in Lupin’s transformation into a global specialty-led biopharma. With VISUfarma...
DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safety Phase 2 clinical trial initiation anticipated before...
Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that...
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fas...
POP Biotechnologies, Inc. (POP BIO), has been awarded a $2.46M USD grant by the National Institutes of Health (NIH) to pursue development of a “mos...
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are bei...
ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, announced it has been awarded a $2.5 mil...
Global pharma major Lupin Limited (Lupin), announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisi...
AstraZeneca announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access th...
Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has approved LEQEMBI® (lecanemab), a humanized...
Booking Health, a leading medical travel facilitator, has announced the expansion of its oncology services to improve international access to advanced st...
© 2025 Biopharma Boardroom. All Rights Reserved.
